scholarly journals The Efficacy and Safety of First-line Chemotherapies for Advanced Biliary Tract Cancer: A Network Meta-analysis

2019 ◽  
Vol 10 (1) ◽  
pp. 257-266 ◽  
Author(s):  
Wei Zheng ◽  
Jie Ying ◽  
Yan Zhou ◽  
Zhiwen Lu ◽  
Ke Min ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
First Line ◽  
Tract Cancer

scholarly journals Efficacy and Safety of Gemcitabine Plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer

2013 ◽  
Vol 24 ◽  
pp. ix34
Author(s):  
Y. Oka ◽  
A. Todaka ◽  
A. Fukutomi ◽  
T. Tsushima ◽  
T. Yokota ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Efficacy And Safety ◽  
First Line ◽  
Tract Cancer ◽  
Line Chemotherapy

Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomized trials.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 4120-4120
Author(s):  
Nobumasa Mizuno ◽  
Juan W. Valle ◽  
Junji Furuse ◽  
Mark Jitlal ◽  
Sandy Beare ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Meta Analysis ◽  
Performance Status ◽  
Progression Free Survival ◽  
Poor Performance ◽  
Japanese Patients ◽  
First Line ◽  
Individual Patient Level ◽  
Tract Cancer

4120 Background: Two recent randomised studies (ABC-02 [UK] and BT22 [Japan]) have demonstrated the superiority of cisplatin and gemcitabine (CisGem) chemotherapy over gemcitabine (Gem) alone for patients with pathologically-proven advanced biliary tract cancer (BTC: cholangiocarcinoma, gallbladder and ampullary cancers). Methods: We performed a meta-analysis of individual patient-level data of these studies to establish the effect of CisGem vs. Gem on progression-free survival (PFS), overall survival (OS) and performed exploratory sub-group analyses. Results: A total of 493 patients, median age 64 years (range 23-84 years) with approximately equal sex distribution, were randomised (ABC-02 study n=410; BT22 study n=83) to receive either CisGem (n=245) or Gem (n=248). CisGem demonstrates a significant improvement in PFS (hazard ratio (HR)=0.64 (95%-CI: 0.53-0.76), p<0.001) and OS (HR=0.65 (95%-CI: 0.54-0.78), p<0.001) over Gem. This effect is most marked in patients with good performance status (PS 0-1): HR for PFS is 0.61 (95%-CI: 0.51-0.74), p<0.001 and HR for OS is 0.64 (95%-CI: 0.53-0.77), p<0.001. CisGem resulted in improved PFS and OS for intra- and extra-hepatic cholangiocarcinomas and gallbladder cancer. The treatment effect between UK and Japanese patients was consistent with respect to OS (HR=0.65, 95%-CI 0.53–0.79 and 0.65, 95%-CI 0.42–1.03, respectively); with similar median survival in the combination arms (median 11.7 and 11.1 months, respectively). Subgroups least likely to benefit included patients with ampullary tumours and poor performance score (PS2). Conclusions: CisGem is the standard of care for the first-line treatment of good-PS patients with advanced BTC regardless of ethnicity. Future studies should aim to enhance the effectiveness of this regimen in the first-line setting and establish the role of subsequent (second-line) therapy. Clinical trial information: ABC-02: NCT00262769, BT22; NCT00380588.

scholarly journals The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (59) ◽  
pp. 100657-100667 ◽  
Author(s):  
Xin-Fang Sun ◽  
Zhi-Kuan He ◽  
Jin-Ping Sun ◽  
Quan-Xing Ge ◽  
Er-Dong Shen
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Pharmacological Interventions ◽  
Tract Cancer

scholarly journals Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: A meta-analysis

2014 ◽  
Vol 20 (47) ◽  
pp. 18001-18012 ◽  
Author(s):  
Heng Liu ◽  
Qi-Di Zhang ◽  
Zheng-Hong Li ◽  
Qing-Qing Zhang ◽  
Lun-Gen Lu
Keyword(s):  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Tract Cancer
Sign in / Sign up

Export Citation Format

Share Document